Leonard Bell

clinical and business skills to Alexion. He is one of the Alexion scientists who developed Soliris® (eculizumab), the company's first product and the first in a new class of therapies to inhibit terminal complement. He also played a critical role in the regulatory submission, approval and introduction of Soliris in 2007. He continues to guide the company's expansion into major markets worldwide, as well as its ongoing research and development programs focused on hematological diseases, cancer and autoimmune disorders. Dr. Bell led Alexion through an initial public offering in 1996, and he has secured financing totaling approximately $800 million to fund development and operations since the company's inception in 1992. Today, Alexion is a profitable, rapidly growing global biopharmaceutical firm.

Prior to founding Alexion, Dr. Bell was an Assistant Professor of Medicine and Pathology and co-Director of the Program in Vascular Biology at the Yale University School of Medicine. Dr. Bell also served as an attending physician at the Yale-New Haven Hospital. He remains on the faculty of the Yale University School of Medicine as an Adjunct Assistant Professor of Medicine and Pathology. Dr. Bell's work has resulted in more than 20 scientific publications and nine patent applications. He continues to guide the company's expansion into major markets worldwide, as well as its ongoing research and development programs focused on severe disease states, including hematologic and kidney diseases, neurologic disorders, ophthalmic, transplant, other inflammatory disorders, and cancer.

Dr. Bell received his bachelor's degree from Brown University and M.D. from Yale University School of Medicine.